← Back to Screener
Aurinia Pharmaceuticals Inc (AUPH)
Price$15.84
Value ScoreC
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-9.66%
Price vs S&P 500 (4W)4.01%
VGM Score68.84
Market Capitalization$2.04B
P/E Ratio (Annual)7.09x
All Metrics
P/CF (Annual)15.02x
Book Value / Share (Quarterly)$4.34
P/TBV (Annual)3.64x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)28.31%
Cash Flow / Share (Quarterly)$1.27
Price vs S&P 500 (YTD)-8.85%
Gross Margin (TTM)89.74%
Net Profit Margin (TTM)99.97%
EPS (TTM)$2.17
10-Day Avg Trading Volume1.43M
EPS Excl Extra (TTM)$2.17
Revenue Growth (5Y)41.39%
EPS (Annual)$2.07
ROI (Annual)44.17%
Gross Margin (Annual)88.46%
Net Profit Margin (5Y Avg)-83.64%
Cash / Share (Quarterly)$2.89
P/E Basic Excl Extra (TTM)6.83x
Revenue Growth QoQ (YoY)24.40%
P/E Normalized (Annual)7.09x
ROA (Last FY)38.21%
Revenue Growth TTM (YoY)20.62%
EBITD / Share (TTM)$1.05
ROE (5Y Avg)-6.84%
Operating Margin (TTM)41.73%
Cash Flow / Share (Annual)$1.02
P/B Ratio3.59x
P/B Ratio (Quarterly)3.47x
Net Income / Employee (Annual)$957,300
EV / Revenue (TTM)6.91x
Net Interest Coverage (TTM)-7.31x
ROA (TTM)47.61%
EPS Growth QoQ (YoY)53.13%
EV / EBITDA (TTM)14.32x
EPS Incl Extra (Annual)$2.07
Current Ratio (Annual)5.25x
Quick Ratio (Quarterly)4.96x
3-Month Avg Trading Volume1.14M
52-Week Price Return95.80%
EV / Free Cash Flow (Annual)15.22x
P/E Incl Extra (TTM)6.83x
Revenue / Employee (TTM)$994,300
Tangible BV / Share (Quarterly)$4.31
P/S Ratio (Annual)7.20x
Asset Turnover (Annual)0.38x
52-Week High$16.88
Operating Margin (5Y Avg)-99.33%
EPS Excl Extra (Annual)$2.07
CapEx CAGR (5Y)-49.05%
Tangible BV CAGR (5Y)7.70%
26-Week Price Return-1.74%
Quick Ratio (Annual)4.70x
13-Week Price Return7.46%
Total Debt / Equity (Annual)0.12x
Current Ratio (Quarterly)5.55x
Enterprise Value$2.06B
Revenue / Share Growth (5Y)37.00%
Asset Turnover (TTM)0.48x
Book Value / Share Growth (5Y)6.42%
Revenue / Employee (Annual)$943,500
Inventory Turnover (Annual)0.77x
Pretax Margin (Annual)40.33%
Cash / Share (Annual)$3.01
3-Month Return Std Dev37.62%
Gross Margin (5Y Avg)92.36%
Net Income / Employee (TTM)$994,000
ROE (Last FY)49.40%
Net Interest Coverage (Annual)-0.61x
EPS Basic Excl Extra (Annual)$2.07
P/FCF (TTM)12.22x
Receivables Turnover (TTM)6.66x
EV / Free Cash Flow (TTM)12.37x
Total Debt / Equity (Quarterly)0.11x
EPS Incl Extra (TTM)$2.17
Receivables Turnover (Annual)7.26x
ROI (TTM)55.97%
P/S Ratio (TTM)6.83x
Pretax Margin (5Y Avg)-95.04%
Revenue / Share (Annual)$2.04
Tangible BV / Share (Annual)$4.36
Forward P/E14.36x
Price vs S&P 500 (52W)71.43%
P/E Ratio (TTM)6.83x
EPS Growth TTM (YoY)684.89%
Year-to-Date Return-0.69%
5-Day Price Return3.46%
EPS Normalized (Annual)$2.07
ROA (5Y Avg)-6.26%
Net Profit Margin (Annual)101.47%
Month-to-Date Return3.33%
Cash Flow / Share (TTM)$-0.49
EBITD / Share (Annual)$0.90
Operating Margin (Annual)37.06%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)12.20x
ROI (5Y Avg)-7.14%
P/E Excl Extra (TTM)6.83x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$2.17
P/TBV (Quarterly)3.49x
P/B Ratio (Annual)3.62x
Inventory Turnover (TTM)0.66x
Pretax Margin (TTM)44.83%
Book Value / Share (Annual)$4.39
Price vs S&P 500 (13W)-0.79%
Beta1.42x
P/FCF (Annual)15.04x
Revenue / Share (TTM)$2.17
ROE (TTM)64.48%
52-Week Low$7.29
vGradeC
gGradeB
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 260.25est. 0.20
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.92
3.92
3.92
3.92
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AUPHAurinia Pharmaceuticals Inc | C | B | B | $15.84 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Aurinia Pharmaceuticals is a biopharmaceutical company specializing in autoimmune diseases with significant unmet medical needs. The company commercializes LUPKYNIS (voclosporin), the first and only FDA-approved oral therapy for active lupus nephritis in adult patients, and is developing aritinercept, a dual BAFF/APRIL inhibitor for additional autoimmune indications.